Home › Funds › Boussard & Gavaudan Investment Management LLP › ALNY

Boussard & Gavaudan Investment Management LLP position in ALNY

ALNYLAM PHARMACEUTICALS INC · Health Care

Boussard & Gavaudan Investment Management LLP reported holding 32,000 shares of ALNY (ALNYLAM PHARMACEUTICALS INC) in its Q1 2026 13F filing — a position valued at US$40.8M, representing 4.47% of its reported portfolio and ranking #7 among its reported holdings. Boussard & Gavaudan Investment Management LLP has disclosed ALNY holdings in 5 of the last 7 reported quarters, going back to Q3 2024.

Latest position (Q1 2026)32.00K sh
Reported value held$40.81M
Portfolio Weight4.47%
First reportedQ3 2024
Last changeAdd
Updated2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

How Boussard & Gavaudan Investment Management LLP's ALNY position evolved

Boussard & Gavaudan Investment Management LLP first disclosed a stake in ALNY in Q3 2024 at 10,500 shares (US$12.3M). The position peaked in Q1 2026 at 32,000 shares, worth US$40.8M. Across 5 filings, Boussard & Gavaudan Investment Management LLP increased the stake 2 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q1 2026) shows 32,000 shares valued at US$40.8M — an increase of 11,046 shares quarter over quarter.. Notable position changes include a 38% trim in Q4 2024 (shares rose 15% over the following quarter), a 60% increase in Q4 2025 (shares fell 17% over the following quarter), a 53% increase in Q1 2026 (shares fell 8% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2024 10.50K $12.32M New
Q4 2024 6.50K $6.97M Reduce
Q3 2025 13.07K $21.50M New
Q4 2025 20.95K $30.92M Add
Q1 2026 32.00K $40.81M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ALNY and 13F data

ALNY (ALNYLAM PHARMACEUTICALS INC) is a Health Care company. 36 other funds we track also report a position in ALNY — the largest reported positions include T. Rowe Price Investment Management, Inc. (US$1.70B), Baillie Gifford & Co (US$734.5M), Orbis Allan Gray Ltd (US$598.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ALNY

All ALNY fund holders →

FAQ

How long has Boussard & Gavaudan Investment Management LLP held ALNY?

Boussard & Gavaudan Investment Management LLP has disclosed ALNY holdings in 5 of the last 7 reported quarters, going back to Q3 2024.

What is Boussard & Gavaudan Investment Management LLP's current position in ALNY?

As of Q1 2026, Boussard & Gavaudan Investment Management LLP holds 32.00K shares of ALNY (ALNYLAM PHARMACEUTICALS INC), valued at $40.81M, representing 4.47% of its reported portfolio and ranking #7.

Has Boussard & Gavaudan Investment Management LLP been buying or selling ALNY?

In the latest 13F filing (Q1 2026), Boussard & Gavaudan Investment Management LLP increased its position in ALNY. The position peaked in Q1 2026 at 32.00K shares.

Which other funds hold ALNY?

Other major institutional holders of ALNY include T. Rowe Price Investment Management, Inc., Baillie Gifford & Co, Orbis Allan Gray Ltd, among 36 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.